GcMAF: a story of exploitation and lies
Once proclaimed a ‘magic protein’ capable of curing cancer, GcMAF has been proven ineffective. The case sheds light on how far scammers are willing to go to exploit desperate cancer patients and their families for financial gain.
Miracle cure?
Two decades ago, stories began to surface about a so-called “silver bullet” for diseases ranging from cancer to HIV and autism: a protein called GcMAF. Studies that “prove” GcMAF’s curative powers were conducted by unethical doctors, profiteering clinics and devious healthcare workers. Scammers even spun conspiracy theories in which non-existent doctors have been murdered because of their GcMAF knowledge.

Too good to be true
However, numerous analyses by third parties have never identified any active mechanisms to explain the protein’s claimed properties. The protein has also never been proven an effective cancer treatment. Publications asserting its efficacy were retracted by respected scientific journals.
Debunking junk science
In August 2017, Snopes.com transparently documented a 20-year timeline of the scams and quackery surrounding GcMAF, illustrating just how powerful profiteers can be when patients and scientists are desperate for a scientifically validated treatment. The ACF played a vital role in uncovering the truth behind this sham treatment.

Notre vision sur le traitement du cancer
NOTRE PROMESSE
-
Nous investissons dans la recherche scientifique la plus prometteuse pour réaliser des progrès certains dans la lutte contre le cancer.
-
Améliorer et prolonger la vie des patients est notre seule cible. Le retour financier ne fait pas partie de nos objectifs.
-
Nous identifions des potentiels inexploités dans la recherche sur le cancer qui amèneront des solutions pragmatiques pour les patients dans le besoin.
-
Nous cherchons à obtenir un impact et pour ce faire, nous investissons nos ressources là où nous pensons pouvoir réaliser rapidement des progrès.
-
Chaque cancer mérite la même attention, indépendamment de critères de prévalence ou de rentabilité.